Introduction
============

Hydroxyethyl starches are almost exclusively excreted renally, for the larger molecules only after hydrolysis by amylase to smaller fragments which can be filtered glomerularly. A new specification, HES 130/0.4 (Voluven^®^), was developed in order to improve pharmacokinetics by more rapid metabolism while preserving efficacy of volume effect compared to HES 200/0.5 (6%). In this study, the dependency of pharmacokinetics of HES 130/0.4 on renal function was studied according to GCP after fully informed consent.

Patients and methods
====================

Prospectively 19 volunteers (m, f) with different degrees of stable, non-anuric renal dysfunction, ranging from almost normal creatinine clearance CL~cr~ (80 to \< 120), mild (50 to \< 80), moderate (30 to \< 50), to severe (15 to \< 30) renal impairment (mean: 50.6 ml/min/1.73 m^2^), were given a single infusion of 500 ml 6% HES 130/0.4 over 30 min. HES serum levels were measured at 0, 5, 10, 30, 60, 120, 240, 360, 480 min, 24 h, 48 h, and 72 h after start of infusion as well as urinary excretion until 72--96 h. CL~cr~ using urine collections had been obtained at least twice before and twice after dosing. Standard pharmacokinetic calculations and regression analysis were performed (primary parameters: area under the curve AUC~0-inf~, C~max~).

Results
=======

AUC~0-inf~ clearly depended on renal function comparing subjects with CL~cr~ below to ≥ 50 (ratio 1.73; 95% confidence interval: 1.44, 2.07). This means that a more than doubled AUC could be excluded. Half-life for drug elimination from the central (= blood) compartment in a two-compartment model increased from 2.6 h at CL~cr~ ≥ 50 to 4.9 h in subjects with CL~cr~ \< 50. C~max~ (mean: 4.34 mg/ml) as well as terminal half-life from the model independent approach (mean: 16.1, range 14.1--18.9 h) were not affected by renal impairment. At CL~cr~ ≥ 30, 59% of the drug could be retreived in urine, vs 51% at CLcr 15 to \< 30. The mean molecular weight of HES in serum was 62,704 D at 30 min, with a tendency to lower values with increased renal impairment. Also, higher pre-dose amylase levels correlated with lower baseline CL~cr~. No serious AE or deterioration in CL~cr~ occurred.

Conclusions
===========

500 ml of HES 130/0.4 (6%) can be safely administered to patients even with severe renal impairment as long as urine flow is preserved. Pharmacokinetics of HES 130/0.4 (6%) in subjects with moderate to severe renal impairment (CL~cr~ 15 to \< 50 ml/min/1.73 m^2^) resembles that of HES 200/0.5 (6%) in healthy volunteers.
